Director
DIN: 01623171
Navin Deshlahra is currently associated with 2 companies in various capacities such as Director and Designated Partner. They serve as a Director at ASPIRE PHARMACEUTICALS PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 01623171.Navin Deshlahra has previously been associated with 2 companies in roles such as Additional Director and Director.Navin Deshlahra is currently involved in 2 different roles. Their most recent position is with SAFE-W PHARMA LLP as a Designated Partner. The first company Navin Deshlahra was appointed to as a director was ASPIRE PHARMACEUTICALS PRIVATE LIMITED. Navin Deshlahra is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
Navin Deshlahra is currently associated with 2 companies in various capacities such as Director and Designated Partner. They serve as a Director at ASPIRE PHARMACEUTICALS PRIVATE LIMITED and have other roles in different companies. They are registered with the Ministry of Corporate Affairs (MCA) of India and hold a DIN of 01623171.Navin Deshlahra has previously been associated with 2 companies in roles such as Additional Director and Director.Navin Deshlahra is currently involved in 2 different roles. Their most recent position is with SAFE-W PHARMA LLP as a Designated Partner. The first company Navin Deshlahra was appointed to as a director was ASPIRE PHARMACEUTICALS PRIVATE LIMITED. Navin Deshlahra is not disqualified by the Registrar of Companies under Section 164(2), and their DIN has not been deactivated due to failure to file the DIR-3 KYC Form.
2
Male
India
Call +91 81049 46419 and we'll pull the verified contact details for you.
Current Companies (1)
Current LLPs (1)
Past Companies (2)
4y 5m 2y 3m Interval
| Company Name | Designation | Date of Appointment |
|---|---|---|
| ASPIRE PHARMACEUTICALS PRIVATE LIMITED | Director | 30-Sep-2023 |